Selectivity Mechanism of ATP-Competitive Inhibitors for PKB and PKA

Author:

Wu Ke1,Pang Jingzhi1,Song Dong1,Zhu Ying1,Wu Congwen1,Shao Tianqu1,Chen Haifeng12

Affiliation:

1. State Key Laboratory of Microbial Metabolism; Department of Bioinformatics and Biostatistics; College of Life Sciences and Biotechnology; Shanghai Jiaotong University; 800 Dongchuan Road Shanghai 200240 China

2. Shanghai Center for Bioinformation Technology; 1275 Keyuan Road Shanghai 200235 China

Funder

Center for HPC at Shanghai Jiao Tong University

Ministry of Science and Technology of China

National High-tech R&D Program of China

National Natural Science Foundation of China

Innovation Program of the Shanghai Education Committee

Medical Engineering Cross Fund of Shanghai Jiaotong University

Publisher

Wiley

Subject

Molecular Medicine,Biochemistry,Drug Discovery,Pharmacology,Organic Chemistry

Reference27 articles.

1. [The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia];Dos Santos;Bull Cancer,2006

2. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer;Gao;Biochem Biophys Res Commun,2003

3. The phosphatidylinositol 3-kinase-AKT pathway in human cancer;Vivanco;Nat Rev Cancer,2002

4. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A;Daaka;Nature,1997

5. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics;Zeng;Bioorg Med Chem Lett,2010

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3